Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Primary Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02760030
What this trial is testing

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor and/or Progesterone Receptor PositiveHER2/Neu NegativeStage IA Breast Cancer+6 more
Ohio State University Comprehensive Cancer Center 14
Testing effectiveness (Phase 2)Study completedNCT00841828
What this trial is testing

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 102
Testing effectiveness (Phase 2)Study completedNCT00532857
What this trial is testing

Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab

Who this might be right for
Breast Cancer
Jungsil Ro 53
Early research (Phase 1)Study completedNCT03236974
What this trial is testing

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

Who this might be right for
Postmenopausal Women With ER+ HER2- Primary Breast Cancer
AstraZeneca 49
Large-scale testing (Phase 3)Active Not RecruitingNCT06126640
What this trial is testing

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Who this might be right for
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd. 1,615
Testing effectiveness (Phase 2)Ended earlyNCT00820924
What this trial is testing

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 23
Not applicableActive Not RecruitingNCT03503799
What this trial is testing

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

Who this might be right for
Primary Invasive Breast CancerEstrogen Receptor Positive TumorHuman Epidermal Growth Factor Receptor 2 Negative Tumor
North Eastern German Society of Gynaecological Oncology 1,191
Early research (Phase 1)Study completedNCT03109977
What this trial is testing

Imaging With a New Agent That Finds a Cancer Protein Called HER2

Who this might be right for
HER2-positive CarcinomaHER2-positive Primary Malignancy
Memorial Sloan Kettering Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT03628066
What this trial is testing

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Who this might be right for
Breast Cancer
NSABP Foundation Inc 24